S 3578

Drug Profile

S 3578

Latest Information Update: 11 Jun 2004

Price : $50

At a glance

  • Originator Shionogi
  • Class Cephalosporins
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 17 May 2004 Discontinued - Phase-I for Bacterial infections in Japan (Parenteral)
  • 05 May 2004 A preclinical study has been added to the pharmacokinetics and Bacterial Infections pharmacodynamics sections
  • 11 Nov 2002 Phase-I clinical trials in Bacterial infections in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top